Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.53 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL410457 | 0.98 | ALDH1A1 (0.60) | ALDH1A1HMOX2EGLN3CYP19A1ESR1 | |
| SCHEMBL7241523 | 0.87 | ALDH1A1 (0.72) | ALDH1A1HMOX2EGLN3CYP19A1 | |
| SCHEMBL10784675 | 0.85 | ALDH1A1 (0.58) | ALDH1A1HMOX2EGLN3CYP19A1PLA2G4A | |
| SCHEMBL10780856 | 0.82 | ALDH1A1 (0.55) | ALDH1A1HMOX2EGLN3PLA2G4A | |
| SCHEMBL10780853 | 0.81 | EGLN3 (0.65) | ALDH1A1EGLN3 | |
| SCHEMBL10391423 | 0.80 | TBXA2R (0.55) | ALDH1A1PLA2G4A | |
| SCHEMBL18985082 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HMOX2EGLN3CYP19A1 | |
| SCHEMBL10576973 | 0.79 | HMOX2 (0.60) | ALDH1A1HMOX2EGLN3CYP19A1 | |
| SCHEMBL412255 | 0.79 | — | — | |
| SCHEMBL10785171 | 0.79 | TBXA2R (0.57) | ALDH1A1PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0347199-B1 | SHAMPOO COMPOSITION | UNILEVER PLC (GB) | 1992-09-09 | — | — | EP | claimed |
| EP-0347199-A2 | Shampoo composition | UNILEVER PLC (GB) | 1989-12-20 | — | — | EP | claimed |
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | Changzhou University (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-09-30 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | QUEENS UNIVERSITY AT KINGSTON (CA) | 2012-01-26 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2011-12-29 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| WO-2008151437-A1 | HEME-OXYGENASE INHIBITORS AND USE OF THE SAME IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM | OSTA BIOTECHNOLOGIES (CA) | 2008-12-18 | — | — | WO | disclosed |
| EP-0862433-B1 | TOPICAL FOAMABLE PHARMACEUTICAL COMPOSITION FOR TREATING SKIN DISEASES INDUCED BY OVAL PITYROSPORUM | PF MEDICAMENT (FR) | 2002-09-11 | — | — | EP | disclosed |
| EP-0347199-B1 | SHAMPOO COMPOSITION | UNILEVER PLC (GB) | 1992-09-09 | — | — | EP | disclosed |
| EP-0347199-A2 | Shampoo composition | UNILEVER PLC (GB) | 1989-12-20 | — | — | EP | disclosed |
| EP-0347199-A2 | Shampoo composition | UNILEVER PLC (GB) | 1989-12-20 | — | — | EP | disclosed |
| EP-0224076-A1 | Azolyl ether ketones and alcohols | BAYER AG (DE) | 1987-06-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319459-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | TXNRD2, HMOX1, HMOX2 | ALDH1A1 452/4885HMOX2 3/4885EGLN3 346/4885 |
| US-20210299126-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | ALDH1A1 373/4885HMOX2 55/4885EGLN3 364/4885 |
| US-20140155445-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | ALDH1A1 394/4885HMOX2 2/4885EGLN3 241/4885 |
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | PTMS, CBS, CHAMP1 | ALDH1A1 1808/4885HMOX2 3275/4885EGLN3 3194/4885 |
| US-20120020915-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | ALDH1A1 394/4885HMOX2 2/4885EGLN3 241/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | ALDH1A1 438/4885HMOX2 2/4885EGLN3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.